

PRESIDENTE DEL CONGRESSO

Pierfranco Conte

OSPITE INTERNAZIONALE

Charles Perou

BOARD

Alberto Bottini

Luigi Dogliotti

Francesco Cognetti

Luca Gianni

Pierfranco Conte

Giorgio Mustacchi

Sabino De Placido

Paolo Pronzato

SEGRETERIA ORGANIZZATIVA

OVER Srl

Via Pagliari, 4 - 26100 Cremona

TEL 0372 23310 - FAX 0372 569605

gloria.platti@overgroup.eu

IL CORSO È STATO ACCREDITATO PER LE SEGUENTI
DISCIPLINE: ANATOMIA PATOLOGICA, BIOLOGIA,
ONCOLOGIA E RADIOTERAPIA

CON IL CONTRIBUTO INCONDIZIONATO DI



bjcclub
breastJournalClub

29-30 NOVEMBRE 2013

PADOVA
HOTEL PLAZA
C.so Milano, 40

PROGRAMMA

29 Novembre 2013

16:00

Benvenuto e apertura lavori
P.F. Conte, L. Dogliotti

16:15

Presentazione e premiazione Matthew Ellis
P.F. Conte, A. Bottini

16:30

Comprehensive molecular portraits of human breast tumours
C. Perou

17:30

Discussione
S Piccolo, G. Mustacchi

18:30

Conclusioni
P.F. Conte

30 Novembre 2013

09:30

PRESENTAZIONE LAVORI UNDER 40
Moderatori: **A. Berruti, M. Mottolose, S. De Placido**

Discussant: **L. Del Mastro**

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Presenter: **D. Generali**

G. Allevi, C. Strina, D. Andreis, V. Zanoni, L. Bazzola, S. Bonardi, C. Foroni, M. Milani, M.R. Cappelletti, F. Gussago, S. Aguggini, R. Giardini, M. Martinotti, S.B. Fox, A.L. Harris, A. Bottini, A. Berruti, D. Generali

Br J Cancer. 2013 Apr 30;108(8):1587-92. doi: 10.1038/bjc.2013.1

Discussant: **A. Frassoldati**

Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis.

Presenter: **V. Guarneri**

M.V. Dieci, E. Barbieri, F. Piacentini, G. Ficarra, S. Bettelli, M. Dominici, P.F. Conte, V. Guarneri
Ann Oncol. 2013 Jan;24(1):101-8. doi

Discussant: **M. De Laurentiis**

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.

Presenter: **M. Clavarezza**

M. Clavarezza, M. Turazza, E. Aitini, S. Saracchini, O. Garrone, A. Durando, S. De Placido, G. Bisagni, A. Levaggi, C. Bighin, E. Restuccia, R. Scalammogna, A. Galli, L. Del Mastro
Breast. 2013 Apr 3

10:30

NEW GENERATION OF TAXANES IN MBC: WORK IN PROGRESS
Moderatori: **V. Adamo, A. Sapino, M.T. Ionta**

C. Tondini

Studio Effect - Evaluation of the efficacy and impact on patient functioning of two doses of nab-paclitaxel in elderly (>65 yrs) breast cancer patients

E. Zafarana

Studio SNAP (A randomized phase II study evaluating three different schedules of nab-paclitaxel as maintenance therapy in metastatic breast cancer)

C. Tondini

11:15

Pausa

11:30

NEW GENERATION OF TAXANES IN MBC: WORK IN PROGRESS

Moderatori: **G. Arpino, G. Bianchini, M. Cazzaniga**

Studio ETNA - Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer

nab-paclitaxel 150 mg/m² day 1, 8, 15 for 4 cycles 28 days followed by AC or FEC for 4 cycles vs Weekly paclitaxel for 4 cycles followed by AC or FEC for 4 cycles both followed by surgery

F. Puglisi

Studio ABRAMYO - Phase I-II, multicenter open label study in patients with previously untreated metastatic breast cancer

Nab-paclitaxel 100 → 125 mg/m² and with LDox 20 → 25 mg/m² will be administered on days 1, 8, 15 of a 28-day cycle until disease progression

P. Papaldo

Studio TENACITY - Phase 2/3, multi-center, open-label, randomized study of weekly Nab-paclitaxel in combination with gemcitabine or carboplatin, vs gemcitabine / carboplatin, as first-line treatment in TNMBC

Abraxane 125mg/m², Gemcitabine 1000mg/m², Carboplatin AUC2 days 1,8 cycles 21 days

P.F. Conte, V. Guarneri

13:15

Round Table Board BJClub

13:45

Conclusioni e compilazione questionario ECM

14:15

Fine Lavori

bjclub
breastjournalclub